{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:39:03Z","timestamp":1793036343917,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10147-026-03179-9","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:35:34Z","timestamp":1788366934000},"page":"2702-2710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse event-related discontinuation of maintenance Bacillus Calmette\u2013Gu\u00e9rin therapy and oncological outcomes in non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Ryota","family":"Nakayasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-9695","authenticated-orcid":false,"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"5","key":"3179_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182(5):2195\u20132203","journal-title":"J Urol"},{"issue":"1","key":"3179_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European Association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394","journal-title":"Eur Urol"},{"issue":"3","key":"3179_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E et al (2022) Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(3):244\u2013258","journal-title":"Ann Oncol"},{"issue":"4","key":"3179_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI et al (2024) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol 211(4):533\u2013538","journal-title":"J Urol"},{"issue":"1","key":"3179_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12885-021-07966-7","volume":"21","author":"M Miyake","year":"2021","unstructured":"Miyake M, Iida K, Nishimura N et al (2021) Non-maintenance intravesical Bacillus Calmette-Guerin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer 21(1):266","journal-title":"BMC Cancer"},{"issue":"10","key":"3179_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.70091","volume":"6","author":"M Miyake","year":"2025","unstructured":"Miyake M, Tokumaru J, Oi H et al (2025) Real-world use of maintenance bacillus Calmette-Guerin therapy in patients with non-muscle-invasive bladder cancer in Japan: ASUKA study. BJUI Compass 6(10):e70091","journal-title":"BJUI Compass"},{"issue":"6","key":"3179_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.urology.2008.12.039","volume":"73","author":"T Takeda","year":"2009","unstructured":"Takeda T, Kikuchi E, Yuge K et al (2009) Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 73(6):1318\u20131322","journal-title":"Urology"},{"issue":"10516","key":"3179_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H et al (2025) Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 406(10516):2221\u20132234","journal-title":"Lancet"},{"issue":"8","key":"3179_CR9","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J et al (2025) Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 31(8):2806\u20132814","journal-title":"Nat Med"},{"issue":"1","key":"3179_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/iju.15309","volume":"31","author":"JH Ku","year":"2024","unstructured":"Ku JH, Lee LS, Lin TP et al (2024) Risk stratification and management of non-muscle-invasive bladder cancer: a physician survey in six Asia-Pacific territories. Int J Urol 31(1):64\u201371","journal-title":"Int J Urol"},{"key":"3179_CR11","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Hoeltl W, Bono AV, Group EG-UTC. The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial. Eur Urol 2003;44(4):423\u20138.","DOI":"10.1016\/S0302-2838(03)00371-3"},{"issue":"9","key":"3179_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101166","volume":"14","author":"G Radha","year":"2021","unstructured":"Radha G, Lopus M (2021) The spontaneous remission of cancer: current insights and therapeutic significance. Transl Oncol 14(9):101166","journal-title":"Transl Oncol"},{"key":"3179_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073","author":"S Jiang","year":"2022","unstructured":"Jiang S, Redelman-Sidi G (2022) BCG in bladder cancer immunotherapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14133073","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3179_CR14","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1111\/cas.15539","volume":"113","author":"H Otsuka","year":"2022","unstructured":"Otsuka H, Kita Y, Ito K et al (2022) Immune-related adverse events in urothelial cancer patients: adjustment for immortal time bias. Cancer Sci 113(11):3912\u20133921","journal-title":"Cancer Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03179-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03179-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03179-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:04:39Z","timestamp":1793034279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03179-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3179"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03179-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Kyoto University Hospital (Approval No. R1581-5). Information regarding the study was disclosed on the institutional website, and patients were provided the opportunity to opt out of participation. The requirement for obtaining informed consent from participants was waived owing to the retrospective nature of this study.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}